Combination Therapy Effective Against Mantle Cell Lymphoma

Jia Ruan, M.D., Ph.D. Associate Professor of Clinical Medicine Weill Cornell Medicine Lymphoma Program Division of Hematology & Medical Oncology New York, NY 10021MedicalResearch.com Interview with:
Jia Ruan, M.D., Ph.D.
Associate Professor of Clinical Medicine
Weill Cornell Medicine
Lymphoma Program
Division of Hematology & Medical Oncology
New York, NY 10021

 

Medical Research: What is the background for this study? What are the main findings?

Dr. Ruan: Mantle cell lymphoma is an uncommon subtype of non-Hodgkin lymphoma that primarily affects elderly populations. Conventional chemotherapy regimens are generally not curative, and may not be tolerated by many patients, underscoring the need for treatment alternatives.  Previous experience with immunomodulatory compound lenalidomide has shown favorable activity and was well tolerated in patients with relapsedMantle cell lymphoma.  We evaluated the efficacy and safety of the biologic combination with lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma (MCL).

The main findings of the study showed that the combination was effective and generally well tolerated when given as induction and maintenance treatment. The overall response rate was 92%, with complete response rate of 64% in the 36 evaluable patients. Median duration of response has not been reached at a median follow up of 30 months.   Treatment was outpatient-based and quality-of-life was preserved for most patients.

Medical Research: What should clinicians and patients take away from your report?

Dr. Ruan: Our study showed that outpatient-based biologic combination of lenalidomide plus rituximab can be considered as a useful option of initial treatment for some patients, particularly those who wish to avoid or cannot tolerate more aggressive approaches.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Ruan: Further studies are warranted in a larger scale and with longer follow-up to evaluate the long-term outcome with biologic combination, as well as a better assessment of its value relative to other mantle-cell lymphoma  regimens.

Citation:

Jia Ruan, M.D., Ph.D., Peter Martin, M.D., Bijal Shah, M.D., Stephen J. Schuster, M.D., Sonali M. Smith, M.D., Richard R. Furman, M.D., Paul Christos, Dr.P.H., Amelyn Rodriguez, R.N., Jakub Svoboda, M.D., Jessica Lewis, P.A., Orel Katz, P.A., Morton Coleman, M.D., and John P. Leonard, M.D.

N Engl J Med 2015; 373:1835-1844
November 5, 2015DOI: 10.1056/NEJMoa150523

 

Jia Ruan, M.D., Ph.D. (2015). Combination Therapy Effective Against Mantle Cell Lymphoma 

Leave a Reply

Your email address will not be published.